HRS-5632
Phase 2Small molecule
HRS-5632 is one of 7 small molecule programs targeting Dyslipidemia. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
4 competitors in Dyslipidemia
#DrugCompanyPhaseTrials
1Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Xuezhikang
Luye Pharma Group Ltd.Phase 3
HRS-5632
FFujian Shengdi Pharmaceutical Co., Ltd.
Phase 2
Pueraria Lobata
JJiangxi University of Traditional Chinese Medicine
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HRS-5632. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details